[The clinico-laboratory dynamics in the reaferon treatment of glomerulonephritis patients with the nephrotic syndrome]. / Kliniko-laboratornaia dinamika pri lechenii reaferonom bol'nykh glomerulonefritom s nefroticheskim sindromom.

Overall 40 chronic glomerulonephritis patients with nephrotic syndrome were treated by reaferon. All the patients underwent clinical and laboratory examinations and nephric biopsy. As a result of the treatment, all the patients demonstrated an increase of the level of glomerular filtration, stabilization of protein and lipid metabolism along with the lowering of diurnal proteinuria. Reaferon exerted a beneficial effect on cellular factors of immunity. In some cases, the use of reaferon can be a definite alternative of the conventional treatment methods.

[Anti-infectious immunity and bacteriuria in patients with the nephrotic syndrome]. / Protivoinfektsionnyi immunitet i bakteriuriia u bol'nykh s nefroticheskim sindromom.

The study was made of antiviral antibodies to respiratory viruses, mycoplasma, O-streptolysin, of qualitative and quantitative characteristics of bacteriuria in 52 patients with nephrotic syndrome (NS) due to glomerulonephritis against 18 NS control subjects without glomerulonephritis. Significant differences between the groups appeared in the titers of antibodies to Coxsackie and influenza A viruses. O-streptolysin. Persistence of viral latent infection in NS is suggested as well as a trigger role of viruses in the disease onset and that of other urinary inflammatory affections whose incidence is now on the increase.

[Serodiagnosis of patients with glomerulonephritis]. / Serodiagnostika bol'nykh glomerulonefritom.

A comprehensive clinical and morphologic examination of 160 nephrologic inpatients included titration of antibodies to respiratory viruses and to HBsAg and of streptolysin O. A correlation was detected between immunity status parameters and the presence and severity of proteinuria in the patients with chronic glomerulonephritis. Besides routine clinical and laboratory examinations, thorough serologic and virologic studies are necessary for this patient population, for such studies will help determine the trigger mechanism of the disease and thus predict the possible development of the condition.

Vaccination activity of live influenza vaccine in different seasons of the year.

Reactogenicity, immunogenicity and viability of the vaccine virus were studied during vaccination of adults with live allantoic influenza vaccines of the types A (H1N1), A (H3N2) and B in different seasons of the year. Seasonal oscillations of reactogenicity of the vaccines (minimum in summer, maximum in winter) were demonstrated. A decrease in the re-isolation rate of vaccine viruses and in their content in the secretions of the upper respiratory passages was observed in summer. Seasonal oscillations of immunogenicity of the commercial live allantoic influenza vaccine with a marked reduction in its activity in summer were established. The administration of moderately attenuated influenza vaccine viruses in summer results in the production of antibodies up to the level observed in other seasons of the year. Theoretical problems and practical aspects of seasonal oscillations of vaccination activity of live influenza vaccines were studied in connection with the necessity of investigation new vaccine strains in varying seasons of the year.

[Assessment of the prophylactic effectiveness of an inactivated influenza vaccine by immunizing schoolchildren in the springtime]. / Otsenka profilakticheskoi éffektivnosti inaktivirovannoi grippoznoi vaktsiny pri immunizatsii shkol'nikov v vesennii period.

To evaluate the prophylactic effectiveness of influenza inactivated chromatographic vaccine, limited epidemiological observations were made on school children aged 11-14 years in Leningrad, in the autumn of 1981 and the spring of 1982. For immunization, made in a single administration, the vaccine composed of A (H3N2) + +A (H1N1) and containing 3.0-3.4 micrograms of hemagglutinin of each component per 0.2 ml of the preparation was used. Altogether 6928 schoolchildren were under observation; of these, 3686 children were immunized and 3242 children received placebo. The results of questioning and the analysis of morbidity rate among the schoolchildren, both immunized and receiving placebo, showed the safety and low reactogenicity of the vaccine irrespective of the time of the immunization campaign. The immunogenic potency of the preparation, as indicated by all observation results, proved to be higher in spring, than in autumn. The data thus obtained indicate that children immunized in spring were better protected and retained a higher level of protection within 12 months after immunization. The shift of the time of the immunization campaign from autumn to spring increased the immune layer in the groups of children by 16.5%. In 10 months after spring immunization the morbidity rate in influenza and acute respiratory diseases among the vaccinees was found to decrease 1.7 times.

[Cross protection in mice immunized with different anti-influenza preparations]. / Perekrestnaia zashcita u myshei pri immunizatsii razlichnymi protivogrippoznymi preparatami.

Observations in white mice demonstrated the development of resistance to influenza type A virus (H3N2 and H0N1) after vaccination against influenza A (H1N1). The most marked cross protection between these serotypes developed after combined use of inactivated and live moderately attenuated vaccines. The resistance to the homologous influenza A (H1N1) virus after vaccination with different influenza vaccines used by various schedules was approximately similar. The role of common antigens and cellular factors of immunity in the development of cross protection against influenza type A viruses is discussed.